The proposed project is designed to provide data necessary to help stop the spread of HIV infection among all intravenous drug users in and out of treatment. It is crucial that the subjects we study accurately represent the population of IVDUs at risk for HIV infection. In particular, we need to insure adequate representation of women and minorities among whom the virus may be more rapidly spreading. This application proposes to extend our current study and add new subjects. We expect that the new subject group will be demographically similar to our existing sample in which we have 30% women, 60% African American, 10% Hispanic, and 30% Caucasian. We have worked very hard to retain all subjects without regard to gender or racial characteristics. We have designed our recruitment procedures so that our new sample will include men and women, Caucasians, African Americans, and Hispanics. Certainly no potential subject will be excluded due to their gender or race. The research is based in a racially and ethnically diverse community and we will make every effort to insure that our sample fully reflects that diversity. We have proposed to recruit a new cohort of subject which should add sufficient numbers to our existing cohort to strengthen our findings and increase the power of our analyses for various gender and racial subgroups. Native Americans and Asian/Pacific Islanders are not excluded from the research but are not sufficiently represented among IVDUs in this area to provide adequate numbers for statistical analyses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005593-05
Application #
3212058
Study Section
Sociobehavioral Subcommittee (DAAR)
Project Start
1992-07-07
Project End
1994-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fureman, I; Meyers, K; McLellan, A T et al. (1997) Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials. AIDS Educ Prev 9:330-41
Davis, R F; Metzger, D S; Meyers, K et al. (1995) Long-term changes in psychological symptomatology associated with HIV serostatus among male injecting drug users. AIDS 9:73-9
Meyers, K; Metzger, D S; McLellan, A T et al. (1995) Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol 10:577-85
Meyers, K; Metzger, D S; Navaline, H et al. (1994) HIV vaccine trials: will intravenous drug users enroll? Am J Public Health 84:761-6
Cohen, E; Navaline, H; Metzger, D (1994) High-risk behaviors for HIV: a comparison between crack-abusing and opioid-abusing African-American women. J Psychoactive Drugs 26:233-41
Zanis, D A; Metzger, D S; McLellan, A T (1994) Factors associated with employment among methadone patients. J Subst Abuse Treat 11:443-7
Frank, I; Fishman, N (1994) Epidemiology and clinical manifestations of human immunodeficiency virus infection. Semin Roentgenol 29:230-41
Metzger, D S; Woody, G E; McLellan, A T et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6:1049-56
Watkins, K E; Metzger, D; Woody, G et al. (1993) Determinants of condom use among intravenous drug users. AIDS 7:719-23
DePhilippis, D; Metzger, D S; Woody, G E et al. (1992) Attitudes toward mandatory human immunodeficiency virus testing and contact tracing. A survey of intravenous drug users in treatment. J Subst Abuse Treat 9:39-42

Showing the most recent 10 out of 11 publications